Citation Impact
Citing Papers
Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
2015
Tumour-cell invasion and migration: diversity and escape mechanisms
2003 Standout
Identification of Subtypes in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome
2010
Breast cancer
2019 Standout
Targeted Therapy in Breast Cancer
2004
Hallmarks of Cancer: The Next Generation
2011 Standout
Triple-Negative Breast Cancer: An Unmet Medical Need
2011
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
2001
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Hypoxia-Inducible Factors in Physiology and Medicine
2012 StandoutNobel
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
Endogenous human microRNAs that suppress breast cancer metastasis
2008 StandoutNature
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
2011 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
A view on drug resistance in cancer
2019 StandoutNature
Personalized treatment of early-stage breast cancer: Present concepts and future directions
2010
Breast cancer
2016 Standout
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Cancer Metastasis: Building a Framework
2006 Standout
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
2005 Standout
Molecular and protein markers for clinical decision making in breast cancer: Today and tomorrow
2013
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Procedures for the Quantitative Protein Determination of Urokinase and Its Inhibitor, PAI-1, in Human Breast Cancer Tissue Extracts by ELISA
2006
Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis
2012 StandoutNobel
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Fibroblast growth factor signalling: from development to cancer
2010 Standout
uPAR: a versatile signalling orchestrator
2002
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
2009
A test of general relativity using radio links with the Cassini spacecraft
2003 StandoutNature
Essentials of the self-organizing map
2012
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
2018
Glycoproteomic Analysis of Prostate Cancer Tissues by SWATH Mass Spectrometry Discovers N-acylethanolamine Acid Amidase and Protein Tyrosine Kinase 7 as Signatures for Tumor Aggressiveness
2014
Emerging Biological Principles of Metastasis
2017 Standout
Hypoxic gene expression and metastasis
2004
Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes
2007
multifunctional enzymes in cancer
2006
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Angiogenesis and Blood Vessel Invasion as Prognostic Indicators for Node-Negative Breast Cancer
2001
Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
2005
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1
2001
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
2017
Prognostic molecular markers in early breast cancer
2004
Clonal evolution in cancer
2012 StandoutNature
Molecular mechanisms of metastasis in breast cancer—clinical applications
2010
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients
2013
Oxygen Sensing, Homeostasis, and Disease
2011 StandoutNobel
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Raf plus TGFβ-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin
2006
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis
2014
Breast cancer metastasis: markers and models
2005 Standout
Spermidine/Spermine N1-Acetyltransferase-1 Binds to Hypoxia-inducible Factor-1α (HIF-1α) and RACK1 and Promotes Ubiquitination and Degradation of HIF-1α
2007 StandoutNobel
Machine learning for data-driven discovery in solid Earth geoscience
2019 StandoutScience
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Life with Oxygen
2007 StandoutScienceNobel
Cell Migration: Integrating Signals from Front to Back
2003 StandoutScience
Practical Approach to Triple-Negative Breast Cancer
2017
Phenotypic characterization of human colorectal cancer stem cells
2007 Standout
Extreme stability in de novo-designed repeat arrays is determined by unusually stable short-range interactions
2018 StandoutNobel
A Strategy for the Selective Imaging of Glycans Using Caged Metabolic Precursors
2010 StandoutNobel
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
2009 Standout
Breast Cancer Treatment
2019 Standout
THEORY OF PROTEIN FOLDING: The Energy Landscape Perspective
1997 Standout
2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*
2001
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
A Field Guide to Foldamers
2001 Standout
Informational Complexity and Functional Activity of RNA Structures
2004 StandoutNobel
Targeting Signal Transduction Pathways in Colorectal Cancer—More Than Skin Deep
2005
Association of uPA, PAI-1, and uPAR in Nipple Aspirate Fluid (NAF) with Breast Cancer
2003
Cancer Genome Landscapes
2013 StandoutScience
Activatable Photosensitizers for Imaging and Therapy
2010 Standout
Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer
2003
Theory and Experiment in Gravitational Physics
1993
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Chemical Glycoproteomics
2016 StandoutNobel
Urokinase Plasminogen Activator and Its Inhibitor, PAI-1, as Prognostic Markers in Breast Cancer: From Pilot to Level 1 Evidence Studies
2002
Works of Ronald Kates being referenced
PTK7 expression in triple-negative breast cancer.
2013
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up
1999
WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
2013
Urokinase-Type Plasminogen Activator and Its Inhibitor Type 1 Predict Disease Outcome and Therapy Response in Primary Breast Cancer
2004
Clinical Relevance of the Plasminogen Activator Inhibitor Type1 – a Multifaceted Proteolytic Factor
2001
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial
2008
Invasion marker PAI‐1 remains a strong prognostic factor after long‐term follow‐up both for primary breast cancer and following first relapse
1999
Clinical Utility of Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor—1 Determination in Primary Breast Cancer Tissue for Individualized Therapy Concepts
2002
Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer
2013
Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial.
2015
Neural computation and self-organizing maps : an introduction
1992
Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When Used in Combination
2002
Invasion Factors uPA/PAI-1 and HER2 Status Provide Independent and Complementary Information on Patient Outcome in Node-Negative Breast Cancer
2003
Pooled analysis (n=8,377) evaluates predictive impact of uPA and PAI-1 for response to adjuvant therapy in breast cancer
2004
ADAPT: Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer.
2013
Prospective comparison of recurrence score, uPA/PAI-1, central grade and molecular classification in early breast cancer: Interim results from the WSG-Plan B trial.
2011
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer
2019
FGFR4 Arg388 Allele Is Associated With Resistance to Adjuvant Therapy in Primary Breast Cancer
2006
S4-3: Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial.
2011
Long-Term Follow-Up Confirms Prognostic Impact of Pai-1 and Cathepsin D and L in Primary Breast Cancer
2000
Motion of a small body through an external field in general relativity calculated by matched asymptotic expansions
1980
Abstract OT3-2-04: ADAPT - Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer
2015
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
2001
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
2002